Fox Chase Cancer Center Announces Opening Celebration for the Research Institute for Cancer Prevention; Evening Honors Individual Donors, Foundations, and Corporations
PHILADELPHIA (April 7, 2000) -- Fox Chase Cancer Center will celebrate the opening of the nation's first comprehensive Research Institute for Cancer Prevention on Wednesday, April 12 from 6:00 p.m. until 8:00 p.m. The evening event will recognize the generosity of individuals, foundations and corporations.
To celebrate the opening, invited guests will be welcome to tour the Pavilion and talk with researchers and clinicians. Also, guests will view video vignettes of families who tell very personal stories of their battle with cancer and what they are doing to help prevent cancer in their own families through the cancer prevention programs at Fox Chase.
The evening's speaking program begins at 7:15 p.m. with welcoming remarks delivered by Philip E. Lippincott, Chairman of the Board of Directors of Fox Chase Cancer Center. The Center's president, Robert C. Young, M.D. will deliver the keynote speech titled "The Beginning of a Fox Chase Dream."
To date, $37.8 million has been raised for the Prevention Pavilion bringing Fox Chase within grasp of its $38 million fundraising campaign goal. Nonprofit foundations around the country as well as companies based locally and abroad have been very generous in their support.
"Our Board of Directors set the pace early with generous gifts, and many foundation and corporate donors have continued their longtime support of Fox Chase programs with major contributions to this campaign," said Center president Robert C. Young, M.D. "Fox Chase is grateful for these commitments as well as for those of so many first-time donors."
Early leadership gifts included $11.5 million from five foundations: The Connelly Foundation of West Conshohocken, Pa., The Dyson Foundation of Millerton, N.Y., The Kresge Foundation of Troy, Mich., The Pew Charitable Trusts of Philadelphia and The W. W. Smith Charitable Trust of Newtown Square, Pa.
A total of $4.9 million has come from 11 corporate donors:
- Berlex Laboratories, based in New Jersey and Richmond, Calif.;
- BetzDearborn Inc., formerly of Trevose, Pa., a wholly-owned chemical subsidiary of Hercules Inc. of Wilmington, Del.;
- Bristol-Myers Squibb Company, whose oncology division is based in Princeton, NJ;
- Crown Cork & Seal Co. of Philadelphia;
- Novartis Pharmaceuticals Corporation, located in East Hanover, NJ;
- Ortho Biotech Inc. and Janssen Pharmaceutica, New Jersey-based members of the Johnson & Johnson family of companies;
- Rhne-Poulenc Rorer, a Collegeville, Pa.-based subsidiary of Rhne-Poulenc S.A. of Paris, France;
- Rohm and Haas Company of Philadelphia;
- Penn Mutual Life Insurance Company of Horsham, Pa.;
- SmithKline Beecham of Philadelphia and London, England.
Much of this support helped fund construction of the Prevention Pavilion that houses the new Fox Chase research initiative. The building and laboratory equipment represent $22.6 million of the total $38 million campaign while the remaining money has been allocated to endowed faculty chairs and postdoctoral fellowships and new research programs.
Fox Chase raised more than $5.4 million in new gifts and grants by September 1999 in order to meet the Kresge Foundation's 1998 challenge grant of $1.5 million. The grant is one of the largest challenge grants Kresge made in 1998 and is believed to be the largest ever made to a Pennsylvania institution.
Scientific investigations to be pursued in the five-level, 120,000 square foot Research Institute for Cancer Prevention include programs in genetics; genetic epidemiology: the study of disease patterns on a molecular level; risk assessment; behavioral medicine; chemoprevention: the use of medication to prevent cancer; and bioinformatics.
In addition to research laboratories, the Prevention Pavilion will house clinical programs for people at high risk of cancer, including genetically driven cancer screening and counseling.
Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at: www.fccc.edu.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.